Latest Analysis of Imperative Care’s SYMPHONY-PE Trial Suggests Early Thrombectomy May Improve Key Measures of Heart Recovery in Intermediate-Risk Pulmonary Embolism
More Than 500 PE Patients Treated with the Symphony Thrombectomy System Since Commercial Launch
Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced findings from a post-hoc analysis of the SYMPHONY-PE Trial evaluating the effect of early mechanical thrombectomy in patients with intermediate-risk pulmonary embolism (PE). The analysis was published in Circulation: Cardiovascular Interventions in a paper titled “Is There a Golden Hour for Thrombectomy in Intermediate-Risk Pulmonary Embolism? Insights from SYMPHONY-PE.”1
Imperative Care also announced that more than 500 pulmonary embolism (PE) patients in the U.S. have been treated with the Symphony Thrombectomy System, reflecting growing physician adoption and commercial momentum since its market introduction in September 2025.
“We set out to establish a new standard in PE treatment by developing a large-bore system that removes the guesswork from thrombectomy and is designed to enable more efficient procedures and real-time decision-making so physicians can focus on what matters most: the patient,” said Fred Khosravi, Imperative Care’s Chairman and CEO. “Now, with more than 500 PE patients treated since commercial launch, we are encouraged by the growing physician confidence in Symphony and the continued clinical evidence supporting its procedural efficiency and favorable safety profile.”
